LGALS3 and Miyoshi myopathy: As shown in Fig. 8B, proliferation of HLA-A2 XBP1/CD138/CS1-specific CTL was enhanced in response to HLA-A2+ U266 MM cells upon the treatment with anti-GAL-3, but not with anti-HLA-DP/DQ/DR, in an effector (CTL):target (MM cells)-dependent manner (1:1 > 1:0.5 > 1:0.25) (histograms, bar graphs [N = 5]).